

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

NCT07332117

Status RECRUITING
Sponsor Royal Brompton & Harefield NHS Foundation Trust
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (4)

- A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
- Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)
- Subject aged \geq 18 years
- Able to willingly give consent

Exclusion (9)

- Co-morbidities currently requiring enteral feeding
 - Weight loss \geq 10% in preceding 3-6 months
 - Significant musculoskeletal issues that may impact muscle mass
 - End of life care (expected \leq 6 weeks left to live)
 - Previous anti-fibrotic use
- ... and 4 more (see full listing online)

Locations (1 total)

Royal Brompton Hospital, London, United Kingdom